On Oct 30, major Wall Street analysts update their ratings for $Encompass Health (EHC.US)$, with price targets ranging from $110 to $116.
BofA Securities analyst Joanna Gajuk initiates coverage with a buy rating, and sets the target price at $115.
Barclays analyst Andrew Mok CFA maintains with a buy rating, and adjusts the target price from $109 to $116.
RBC Capital analyst Ben Hendrix maintains with a buy rating, and adjusts the target price from $105 to $110.
Truist Financial analyst David S Macdonald maintains with a buy rating, and sets the target price at $116.
Furthermore, according to the comprehensive report, the opinions of $Encompass Health (EHC.US)$'s main analysts recently are as follows:
Encompass Health's earnings results were described as 'refreshing,' reinforcing the company's 'exceptionally strong fundamentals' which are largely shielded from potential election-related risks.
Q3 results for Encompass Health were notably robust, underscored by a 4% EBITDA beat propelled by stronger same-store volumes. The company's stock remains attractive due to solid fundamentals and a degree of protection from election-related dynamics.
Here are the latest investment ratings and price targets for $Encompass Health (EHC.US)$ from 4 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
